跳至主要内容
临床试验/NCT04726956
NCT04726956已完成不适用

A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of Pancreatic Ductal Adenocarcinoma:A Multicenter Study

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine3 个研究点 分布在 1 个国家目标入组 258 人开始时间: 2021年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
258
试验地点
3
主要终点
CA199 and AKR1B10 were detected in the sera of PDAC patients and Benign patients before surgery, as well as in the sera of healthy donors

研究概览

简要总结

The purpose of this study is to clarify the diagnostic significance of AKR1B10 in patients with pancreatic ductal adenocarcinoma, and to combine with CA19-9 to improve the diagnosis rate of pancreatic ductal adenocarcinoma.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • PDAC group:
  • Patients who have undergone radiotherapy, chemotherapy and other tumor-related treatments before surgery;
  • Patients with non-primary pancreatic cancer;
  • Patients undergoing secondary operations;
  • Infected with HIV or AIDS related diseases;
  • Diagnosed as chronic or acute gastroenteritis;
  • Pregnant women;
  • Other situations that are not suitable for this research;
  • Benign group
  • (1) Patients who have undergone related surgical treatment in other hospitals; (2) Patients with a history of malignant tumors;
  • Healthy group:
  • Patients with a history of tumor;
  • Tumors found in medical examinations;
  • History of hepatitis B or C;
  • A history of acute or chronic gastroenteritis, cholecystitis, and cholangitis.

结局指标

主要结局

CA199 and AKR1B10 were detected in the sera of PDAC patients and Benign patients before surgery, as well as in the sera of healthy donors

时间窗: 1 week

次要结局

  • CA125, CEA, and AFP were detected in the sera of PDAC and Benign patients before surgery, as well as in the sera of healthy donors(1 week)

研究者

发起方
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
申办方类型
Other
责任方
Principal Investigator
主要研究者

Lin Zhong

Director of Hepatobiliary and Pancreatic Surgery

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

研究点 (3)

Loading locations...

相似试验